ArticleAmerican journal of hematology2020
Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
Article in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Clinical and Pathological Features That Predict High-Grade B-Cell Lymphomas (HGBCLs) withBiomedicines · 2026Review
- Article
- 2026 Update on the Management of Diffuse Large B-Cell Lymphoma.American journal of hematology · 2026Review
- Integrating bulk and single-cell transcriptome to identify novel gene markers for germinal center B cells (GCB) subtype of diffuse large B-cell lymphoma.Annals of hematology · 2025Article
- From Biopsy to Diagnosis: Navigating Aggressive B-Cell Lymphomas in Practice.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects.International journal of hematology · 2025Review
- Discrepancy of Hans' criteria for clonally related nodal and pericardiac fluid diffuse large B-cell lymphoma with MYD88 L265P mutation.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Artificial intelligence powers regenerative medicine into predictive realm.Regenerative medicine · 2024Review
- Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.Annals of hematology · 2024Article
- Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.Clinical epigenetics · 2024Article
- Association between serum albumin levels and survival in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective study.Translational cancer research · 2023Article
- High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.International journal of experimental pathology · 2023Article
- Article
- ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin.NPJ breast cancer · 2022Article
- An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.EJHaem · 2022Article
- The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice.Frontiers in oncology · 2022Review
- Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.Frontiers in oncology · 2022Article
- Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.Annals of hematology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO). However, GEP is not widely applied in clinical practice and consequently, several algorithms based on immunohistochemistry (IHC) have been developed. Our aim was to evaluate the concordance of COO assignment between the Lymph2Cx GEP assay and the IHC-based Hans algorithm, to decide which model is the best survival predictor. Both GEP and IHC were performed in 359 homogenously treated Swedish and Danish DLBCL patients, in a retrospective multicenter cohort. The overall concordance between GEP and IHC algorithm was 72%; GEP classified 85% of cases assigned as GCB by IHC, as GCB, while 58% classified as non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.